Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS 986141 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BMS 986141 and Rifampin | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS 986141 | DRUG | Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22) |
| Rifampin | DRUG | Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22) |
Inclusion Criteria: 1. Signed Informed Consent 2. Healthy men and women (not of child bearing potential) as determined by medical history, surgical history, physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory tests including coagulation parameters. 3. Subjects with b...
BMS 986141 is an investigational small molecule being developed for cardiovascular conditions including atherothrombotic diseases, ischemic stroke, and thrombosis. It is currently in clinical development and has not been approved by the FDA. The drug is being studied to potentially reduce the chances of additional strokes or mini strokes.
BMS 986141 is a protease activated receptor-4 (PAR-4) antagonist, as indicated by the clinical trial title. It works by targeting this receptor, which is involved in platelet activation and thrombosis. By blocking PAR-4, the drug aims to reduce thrombotic events in conditions like ischemic stroke and atherothrombotic diseases.
BMS 986141 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY on the stock exchange. The company is conducting clinical trials to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of this investigational drug in various patient populations.
BMS 986141 is in Phase 1 of clinical development, according to the overall phase designation. However, one completed trial (NCT02671461) was a Phase 2 study. The drug is investigational and not yet approved by regulatory authorities. All listed trials for BMS 986141 have been completed.
BMS 986141 has been studied in four completed clinical trials. NCT02341638 was a Phase 1 single and multiple ascending dose study in healthy subjects. NCT02671461 was a Phase 2 safety and efficacy study in patients with thrombosis. NCT02922452 and NCT02957448 were Phase 1 drug interaction studies with diltiazem and rifampin, respectively.
Yes, BMS 986141 and BMS-986141 refer to the same drug. The hyphenated version is used in clinical trial titles, while the non-hyphenated form appears in other contexts. Both names identify the same investigational protease activated receptor-4 antagonist being developed by Bristol-Myers Squibb.